About this Research Topic
In the pivotal battle against cancer, one significant hurdle is the ability of cancer cells to adeptly evade immune detection. This evasion is facilitated by mechanisms such as the downregulation of antigen presentation and the orchestration of an immunosuppressive tumor microenvironment. Recent studies have shed light on the complex interplay between cancer cells and the immune system, highlighting how tumors manipulate both innate and adaptive immune responses to their advantage. Despite advancements in understanding these processes, substantial gaps in effective counterstrategies remain, emphasizing the need for innovative therapeutic avenues.
This research topic aims to explore strategies that boost both innate and adaptive immune responses to overcome these challenges. It will focus on the interplay between innate immune responses (dendritic and natural killer activation) and adaptive immunity (T cell priming, memory formation, and B-cell activation). By modulating these pathways and triggering immunogenic induction in cancer cells, therapies aim to overcome malign tumor immune evasion and promote immune system recognition as well as elimination of cancer cells.
Authors are expected to address the challenge of enhancing the immune system’s ability to recognize and eliminate cancer cells. The focus may be on innate immunity, such as activating dendritic cells or natural killer cells to establish a robust first-line defense, or it could target adaptive immunity, particularly through the promotion of T or B cell responses and memory induction for long-term anticancer protection. Recent advances in multiparametric analysis of the systemic immune system and tumor microenvironment will facilitate the assessment of both innate and adaptive immune responses. By utilizing innovative therapeutic approaches, this research aims to improve immune recognition and enhance the elimination of cancer cells.
Therefore, this Research Topic aims to explore innovative strategies that target the immunogenicity of cancer cells, bridging innate and adaptive immune responses for more effective anticancer therapies. We welcome submissions of the following article types: Original research, Brief Research Reports, Reviews, Mini-Reviews, Methods and protocols detailing innovative techniques for cancer immunotherapy research, and Clinical trials and Case report articles which cover but are not limited to:
● Novel methods that trigger/enhance the Immunogenicity of Cancer Cells
● Mechanisms of tumor immune evasion and strategies to overcome this evasion.
● Immunogenic cell death inductors and molecular mechanisms in cancer.
● Interactions between innate and adaptive immunity that have an impact in the tumor microenvironment.
● Development and optimization of anticancer immunotherapies such as cancer vaccines, oncolytic viruses, and immune checkpoint inhibitors, that render cancer cells immunogenic.
● Novel molecular biomarkers that predict patient responses to immunotherapies or highlight potential therapeutic targets related to the immunogenicity of cancer cells.
● Preclinical and clinical studies on combination therapies targeting both innate and adaptive immunity that render cancer cells immunogenic or sensitive to Immunogenic cell death.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
This research topic aims to explore strategies that boost both innate and adaptive immune responses to overcome these challenges. It will focus on the interplay between innate immune responses (dendritic and natural killer activation) and adaptive immunity (T cell priming, memory formation, and B-cell activation). By modulating these pathways and triggering immunogenic induction in cancer cells, therapies aim to overcome malign tumor immune evasion and promote immune system recognition as well as elimination of cancer cells.
Authors are expected to address the challenge of enhancing the immune system’s ability to recognize and eliminate cancer cells. The focus may be on innate immunity, such as activating dendritic cells or natural killer cells to establish a robust first-line defense, or it could target adaptive immunity, particularly through the promotion of T or B cell responses and memory induction for long-term anticancer protection. Recent advances in multiparametric analysis of the systemic immune system and tumor microenvironment will facilitate the assessment of both innate and adaptive immune responses. By utilizing innovative therapeutic approaches, this research aims to improve immune recognition and enhance the elimination of cancer cells.
Therefore, this Research Topic aims to explore innovative strategies that target the immunogenicity of cancer cells, bridging innate and adaptive immune responses for more effective anticancer therapies. We welcome submissions of the following article types: Original research, Brief Research Reports, Reviews, Mini-Reviews, Methods and protocols detailing innovative techniques for cancer immunotherapy research, and Clinical trials and Case report articles which cover but are not limited to:
● Novel methods that trigger/enhance the Immunogenicity of Cancer Cells
● Mechanisms of tumor immune evasion and strategies to overcome this evasion.
● Immunogenic cell death inductors and molecular mechanisms in cancer.
● Interactions between innate and adaptive immunity that have an impact in the tumor microenvironment.
● Development and optimization of anticancer immunotherapies such as cancer vaccines, oncolytic viruses, and immune checkpoint inhibitors, that render cancer cells immunogenic.
● Novel molecular biomarkers that predict patient responses to immunotherapies or highlight potential therapeutic targets related to the immunogenicity of cancer cells.
● Preclinical and clinical studies on combination therapies targeting both innate and adaptive immunity that render cancer cells immunogenic or sensitive to Immunogenic cell death.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
Keywords: Cancer immunogenicity, Anticancer therapies, Innate and adaptive immunity, Immunogenic cell death, Immune system evasion, Immunotherapies
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
